ELA Elabela/Toddler-32


  • Description

  • Application Data


Elabela/Toddler-32 (ELA-32) is an endogenous ligand for the apelin G protein-coupled receptor (GPCR). ELA-32 has a role in improving cardiac output and reducing the severity of pulmonary arterial hypertension (PAH) in cardiovascular disease.

See full description

Application Data

Catalogue number crb1001426
Molecular Weight 3965.1
Sequence (one letter code)


Sequence (three letter code)

H-Gln-Arg-Pro-Val-Asn-Leu-Thr-Met-Arg-Arg-Lys-Leu-Arg-Lys-His-Asn-Cys-Leu-Gln-Arg-Arg-Cys-Met-Pro-Leu-His-Ser-Arg-Val-Pro-Phe-Pro-OH (Disulfide bridge: Cys17-Cys22)

Modifications Disulfide bridge: Cys17-Cys22
Purity >95%
cas 1680205-79-1
Storage -20°C

Couvineau et al., (2020). Elabela/Toddler and apelin bind differently to the apelin receptor. The FASEB Journal, 34(6): 7989. doi: 10.1096/fj.201903029R.

Kuba et al., (2019). Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology. Peptides, 111: 62. doi: 10.1016/j.peptides.2018.04.011.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Elabela/Toddler-32  (ELA-32) has been identified as a new endogenous ligand for the apelin G protein coupled receptor (GPCR). Apelin levels have been shown to be reduced in heart failure and pulmonary arterial hypertension (PAH). ELA-32 delivery could be used to supplement the deficit of apelin. It can be cleaved to shorter forms Elabela/Toddler-21, and Elabela/Toddler-11. Apelin and ELA-32 share almost no sequence homology which is unusual for receptor ligands, it suggests a future for apelin receptor biased agonist design.

Exogenous administration of ELA-32 to rats has been shown to compensate for the downregulation of apelin seen in PAH. Further research into the potential of this peptide as an endogenous agonist reducing the severity of PAH could provide vital therapeutics in the future for cardiovascular disease.

ELA Elabela/Toddler-32

Cat No.Pack SizePriceQty.
Bulk Quote

You may also like…